Reports: NY to use GPS-fitted pill bottles to track thieves
NEW YORK — New York is hoping to battle the theft of highly addictive prescription drugs, such as Oxycontin, by stocking pharmacies with fake pill bottles that are fitted with GPS tracking devices, according to published reports.
The Washington Post reported that Police Commissioner Raymond Kelly said, in prepared remarks provided before a conference Tuesday in California sponsored by former president Bill Clinton’s foundation, that the initiative was sparked by a series of crimes associated with the black market for prescription painkillers.
The initiative is reportedly dubbed “Operation Safety Cap.”
According to a Reuters report, federal and New York Police Department investigators last year seized 9,000 painkillers being sold at an open-air drug market in northern Manhattan.
A database of about 6,000 pharmacies in the New York City area currently is being created by the NYPD, according to the Post. Police offers are expected to visit those pharmacies to recommend better security measures, including the adoption of the GPS-fitted bottles.
To read the entire article by the Post, click here.
Report: Kinney Drugs’ new specialty Rx subsidiary to open mail-order facility in DeWitt
GOUVERNEUR, N.Y. — Specialty pharmacy service provider Noble Health Associates, a newly created subsidiary of regional player Kinney Drugs, is looking to open a mail-order facility in DeWitt, N.Y., according to a local news report.
Director of specialty pharmacy for Noble Health Michael Becker told The Post-Standard that it plans to open the facility in the spring or summer and will employ 31 people.
Noble Health will dispense, by mail, specialty medications for diseases such as AIDS, according to the article. The business in DeWitt will process orders, package the medications and ship them, serving customers throughout the country, The Post-Standard reported.
FDA approves Uceris for ulcerative colitis
SAN DIEGO — The Food and Drug Administration has approved an ulcerative colitis drug made by Santarus, the drug maker said.
Santarus announced the approval of Uceris (budesonide) extended-release tablets for mild to active UC. The company plans to launch the drug in March.
"We are pleased to provide a new option for patients to treat the active phase of mild to moderate ulcerative colitis," Santarus president and CEO Gerald Proehl said. "With the incremental revenue from Uceris and continued growth in our marketed products, we anticipate another robust year of solid financial results for Santarus in 2013."
Proehl said the company expected the drug to have sales of $320 million to $325 million.